medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2018, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2018; 63 (3)

Demographic characteristics of lung cancer and its association with wood smoke exposure in Mexican population

Imaz OV, Green RD, Gerson CR, Alatorre AJ, Martos RG, Green SL, Rodríguez CJ

Language: Spanish
References: 25
Page: 188-193
PDF size: 214.53 Kb.


ABSTRACT

Introduction: Biomass, especially wood smoke, has been proposed as a risk factor for lung cancer, with an increased risk of up to 25 times. There is not a wood smoke exposure index where the increased risk could be used for screening or early diagnosis. Methods: Retrospective, longitudinal, cohort study that analyzes the demographic characteristics of the Mexican population with lung cancer and its association with wood smoke exposure. The study included 123 lung cancer patients treated between 2013 and 2014. The primary endpoint was the association between lung cancer and the rate of wood smoke exposure. Two cohorts were analyzed according to exposure. Results: Almost half of the patients (47.2%) were smokers, with an average of 12.7 packs/year. Likewise, 47.15% had wood-smoke exposure, with an average of 77.5 hours/year. Pathology: 88.6% had non-small-cell lung cancer (69.9% adenocarcinoma, 11.4% squamous and 7.3% other histology), and 11.4% small cell lung cancer. The highest wood smoke exposure was in patients with adenocarcinoma (p ‹ 0.003); those with this exposure had a higher risk of developing lung cancer (p ‹ 0.001). The level of exposure that showed to be significant for lung cancer risk was 61 hours/year (p ‹ 0.001). Conclusions: Wood smoke exposure is a clear risk factor for lung cancer development, especially adenocarcinoma. The cut level of 61 hours/year should be used for screening and early lung cancer detection.


REFERENCES

  1. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001; 93 (11): 824-842.

  2. Secretaría de Salud. Coordinación General de Planeación Estratégica, Dirección General de Información Evaluación del Desempeño. En: Mortalidad 1999. Ciudad de México, México: Talleres de Impresión Gráfica de Arte Mexicano, SA de CV; 2000. pp. 79-90.

  3. Secretaría de Salud. Compendio del Registro Histopatológico de las Neoplasias Malignas en México. México: Dirección General de Epidemiología, Secretaría de Salud; 2003. [Consultada 03 de julio de 2005] Disponible en: https://epidemiologiatlax.files.wordpress.com/2012/10/p_epi_de_los_tumores_malignos_mc3a9xico.pdf.

  4. Alberg AJ, Ford JG, Samet JM; American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132 (3 Suppl): 29S-55S.

  5. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008; 26 (9): 1472-1478.

  6. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008; 26 (15): 2442-2449.

  7. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005; 353 (2): 133-144.

  8. Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol. 2011; 6 (11): 1955-1959.

  9. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007; 25 (5): 561-570.

  10. Fraumeni JF Jr. Respiratory carcinogenesis: an epidemiologic appraisal. J Natl Cancer Inst. 1975; 55 (5): 1039-1046.

  11. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97 (19): 1407-1427.

  12. Prasad R, Singh A, Garg R, Giridhar GB. Biomass fuel exposure and respiratory diseases in India. Biosci Trends. 2012; 6 (5): 219-228.

  13. Perez-Padilla JR, Regalado-Pineda J, Moran-Mendoza AO. La inhalación doméstica del humo de leña y otros materiales biológicos. Un riesgo para el desarrollo de enfermedades respiratorias. Gac Med Mex. 1999; 135: 19-29.

  14. Hernández-Garduño E, Brauer M, Pérez-Neria J, Vedal S. Wood smoke exposure and lung adenocarcinoma in non-smoking Mexican women. Int J Tuberc Lung Dis. 2004; 8 (3): 377-383.

  15. Arrieta O, Campos-Parra AD, Zuloaga C, Avilés A, Sánchez-Reyes R, Manríquez ME et al. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol. 2012; 7 (8): 1228-1234.

  16. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365 (5): 395-409.

  17. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013; 369 (10): 920-931.

  18. National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013; 368 (21): 1980-1991.

  19. Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen. 2011; 18 (3): 109-111.

  20. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012; 307 (22): 2418-2429.

  21. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64 (1): 9-29.

  22. Gutiérrez-Fisac JL, Suárez M, Neira M, Regidor E. Tendencia de los principales factores de riesgo de enfermedades crónicas. España, 2001-2011/12. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad, 2013.

  23. Secretaría de Salud. Encuesta Nacional de Salud y Nutrición 2016 (ENSANUT), Instituto Nacional de Salud Pública, octubre 2016.

  24. Wang J, Xu H, Zhou S, Wang D, Zhu L, Hou J et al. Body mass index and mortality in lung cancer patients: a systematic review and meta-analysis. Eur J Clin Nutr. 2018; 72 (1): 4-17.

  25. Arrieta O, Ramírez-Tirado LA, Báez-Saldaña R, Peña-Curiel O, Soca-Chafre G, Macedo-Perez EO. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the “Hispanic paradox”. Lung Cancer. 2015; 90 (2): 161-166.




2020     |     www.medigraphic.com